ACAD
31.44
+0.5
+1.62%
AEMD
1.42
-0.09
-5.96%
APRI
1.48
0.00
0.00%
ARNA
21.02
+0.76
+3.75%
ATEC
1.96
+0.02
+1.03%
CNAT
5.18
+0.03
+0.58%
CRXM
0.172
+0.002
+1.1176%
CYTX
0.321
+0.01
+3.149%
DXCM
75.91
+2.85
+3.90%
GNMK
9.44
-0.1
-1.05%
HALO
12.1
+0.2
+1.68%
ILMN
194.76
+4.08
+2.14%
INNV
0.117
+0.009
+8.837%
INO
5.56
+0.1
+1.83%
ISCO
1.2
-0.05
-4.00%
ISIS
57.56
0.00
0.00%
LGND
127.97
+1.42
+1.12%
LPTN
2.93
-2.93
-100.00%
MBVX
0.51
0.00
0.00%
MEIP
2.58
-0.02
-0.77%
MNOV
5.05
+0.08
+1.61%
MRTX
5.3
-0.15
-2.75%
MSTX
0.13
-0.01
-5.28%
NBIX
52.62
+0.49
+0.94%
NUVA
64.65
+0.17
+0.26%
ONCS
0.94
+0.05
+5.61%
ONVO
1.96
+0.15
+8.29%
OREX
2.34
-0.05
-2.09%
OTIC
20.35
+0.1
+0.49%
QDEL
33.48
+0.71
+2.17%
RCPT
231.96
0.00
0.00%
RGLS
0.86
+0.01
+1.61%
RMD
74.55
+1.11
+1.51%
SCIE
0
0.00
0.00%
SPHS
1.89
+0.07
+3.85%
SRNE
1.7
0.00
0.00%
TROV
0.85
+0.03
+3.66%
VICL
2.37
+0.03
+1.28%
VOLC
18
0.00
0.00%
ZGNX
12.45
+0.15
+1.22%
ACAD
31.44
+0.5
+1.62%
AEMD
1.42
-0.09
-5.96%
APRI
1.48
0.00
0.00%
ARNA
21.02
+0.76
+3.75%
ATEC
1.96
+0.02
+1.03%
CNAT
5.18
+0.03
+0.58%
CRXM
0.172
+0.002
+1.1176%
CYTX
0.321
+0.01
+3.149%
DXCM
75.91
+2.85
+3.90%
GNMK
9.44
-0.1
-1.05%
HALO
12.1
+0.2
+1.68%
ILMN
194.76
+4.08
+2.14%
INNV
0.117
+0.009
+8.837%
INO
5.56
+0.1
+1.83%
ISCO
1.2
-0.05
-4.00%
ISIS
57.56
0.00
0.00%
LGND
127.97
+1.42
+1.12%
LPTN
2.93
-2.93
-100.00%
MBVX
0.51
0.00
0.00%
MEIP
2.58
-0.02
-0.77%
MNOV
5.05
+0.08
+1.61%
MRTX
5.3
-0.15
-2.75%
MSTX
0.13
-0.01
-5.28%
NBIX
52.62
+0.49
+0.94%
NUVA
64.65
+0.17
+0.26%
ONCS
0.94
+0.05
+5.61%
ONVO
1.96
+0.15
+8.29%
OREX
2.34
-0.05
-2.09%
OTIC
20.35
+0.1
+0.49%
QDEL
33.48
+0.71
+2.17%
RCPT
231.96
0.00
0.00%
RGLS
0.86
+0.01
+1.61%
RMD
74.55
+1.11
+1.51%
SCIE
0
0.00
0.00%
SPHS
1.89
+0.07
+3.85%
SRNE
1.7
0.00
0.00%
TROV
0.85
+0.03
+3.66%
VICL
2.37
+0.03
+1.28%
VOLC
18
0.00
0.00%
ZGNX
12.45
+0.15
+1.22%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

NantKwest Shareholder (NK) Alert:  Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of NantKwest, Inc.; Encourages Investors to Contact the Firm

March 14, 2016 – 2:30 pm

SAN DIEGO, March 14, 2016 /PRNewswire/ — Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by NantKwest, Inc. (NASDAQ: NK) and certain of its officers. NantKwest, a biotechnology company, develops immunotherapeutic agents for various clinical conditions.

Specifically, Johnson & Weaver’s investigation seeks to determine whether certain statements regarding the Company’s business and prospects were false and misleading when made.

On July 28, 2015, NantKwest’s stock traded as high as $38.48, the same day the Company sold 8.3 million shares of stock in its initial public stock offering (the “IPO”), raising $207.2 million in new capital.  However, since the IPO, NantKwest’s stock has imploded, falling from its high of $38.48 on July 28, 2015 to close at $8.37 on March 14, 2016.

On March 11, 2016, NantKwest announced that its interim financial statements for the quarters ended June 30, 2015 and September 30, 2015 should no longer be relied upon due to the errors in the financial statements, mainly attributable to certain stock-based awards to NantKwest’s Chief Executive Officer and Executive Chairman and build-to-suit lease accounting related to one of its research and development and Good Manufacturing Practices facilities. NantKwest management has announced that these errors were the result of a material weakness in its internal controls of financial reporting. NantKwest further acknowledged that “the material weakness, as disclosed in previous filings, is a result of inadequate staffing levels, resulting in insufficient time spent on review and approval of certain information used to prepare our financial statements and the maintenance of effective controls to adequately monitor and review significant transactions for financial statement completeness and accuracy. Management is continuing to assess the effect of the restatement on the Company’s internal control over financial reporting and disclosure controls and procedures and expects to report its conclusions regarding these matters in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015“.

If you are a NantKwest shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you email, please include your phone number.

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com

Logo – http://photos.prnewswire.com/prnh/20160211/332409LOGO

 

SOURCE Johnson & Weaver, LLP

Mast Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results

March 14, 2016 – 5:00 am

SAN DIEGO, March 14, 2016 /PRNewswire/ — Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today reported financial results for the fourth quarter and year ended December 31, 2015.

“Last month we announced that we had completed patient enrollment in our Phase 3 study of vepoloxamer in sickle cell crisis, known as the EPIC study. The study was conducted in 14 countries at more than 75 sites and is the largest placebo-controlled study in sickle cell disease ever concluded. It was a monumental effort to finish enrollment as quickly as possible and I commend the clinical investigators, the patients, and their families for this important achievement,” stated Brian M. Culley, Chief Executive Officer. “Vepoloxamer remains the most clinically-advanced new drug in development for sickle cell disease and we look forward to seeing the top-line results of the EPIC study in the second quarter of 2016.”

“We also recently announced positive data from a Phase 2a study of AIR001 in patients with heart failure with preserved ejection fraction conducted at Mayo Clinic,” continued Mr. Culley. “In this blinded and placebo-controlled study, AIR001 showed a statistically significant improvement in pulmonary capillary wedge pressure during exercise, the pre-specified primary endpoint, and attenuated other hemodynamic derangements of cardiac failure that occur during exercise in HFpEF patients. We look forward to initiation of the next Phase 2 study of AIR001 in the third quarter of this year, a 100-patient multi-center trial to be conducted at the premier clinical centers that make up the Heart Failure Clinical Research Network.”

Fourth Quarter 2015 Operating Results

The Company’s net loss for the fourth quarter of 2015 was $10.2 million, or $0.06 per share (basic and diluted), compared to a net loss of $7.3 million, or $0.05 per share (basic and diluted), for the same period in 2014.

Research and development (R&D) expenses for the fourth quarter of 2015 were $7.2 million, an increase of $2.3 million, or 45%, compared to $4.9 million for the same period in 2014. The increase was due mainly to increases of $0.9 million in external nonclinical study fees and expenses related primarily to research-related manufacturing costs for vepoloxamer ($0.4 million) and nonclinical toxicology studies of vepoloxamer to support a vepoloxamer NDA submission ($0.4 million), $0.9 million in external clinical study fees and expenses related primarily to EPIC study costs ($0.5 million) and costs for the Phase 2 study of vepoloxamer in heart failure ($0.4 million), and $0.4 million in personnel expenses.

Selling, general and administrative (SG&A) expenses for the fourth quarter of 2015 were $2.5 million, an increase of $0.1 million, or 5%, compared to $2.4 million for the same period in 2014.

Year-to-Date Operating Results

The Company’s net loss for the year ended December 31, 2015 was $39.8 million, or $0.25 per share (basic and diluted), compared to a net loss of $28.7 million, or $0.23 per share (basic and diluted), for the same period in 2014.

R&D expenses for the year ended December 31, 2015 were $28.3 million, an increase of $8.9 million, or 45%, compared to $19.4 million for the same period in 2014. The increase was due to increases of  $5.1 million in external nonclinical study fees and expenses, $2.9 million in external clinical study fees and expenses, $0.7 million in personnel costs and $0.2 million in share-based compensation expense.  The increase in external nonclinical study fees and expenses resulted primarily from research-related manufacturing costs for vepoloxamer ($2.9 million), nonclinical toxicology studies of vepoloxamer to support a vepoloxamer NDA submission ($1.8 million) and consulting fees for NDA-readiness activities related to vepoloxamer ($0.4 million).  The increase in external clinical study fees and expenses was related primarily to increases in EPIC study costs ($3.3 million) and the Phase 2 study of vepoloxamer in heart failure  ($0.9 million), offset by decreases in costs for the discontinued Phase 2 study of vepoloxamer in acute limb ischemia ($0.8 million) and AIR001 clinical study expenses ($0.5 million).  The increase in personnel costs resulted primarily from additional regulatory, clinical operations and research-related manufacturing staff hired in 2015.

SG&A expenses for the year ended December 31, 2015 were $11.0 million, an increase of $1.5 million, or 16%, compared to $9.5 million for the same period in 2014. The increase resulted primarily from increases in consulting expenses and personnel costs.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is developing two clinical-stage investigational new drugs for serious or life-threatening diseases and conditions. Vepoloxamer, the Company’s lead product candidate, is in Phase 3 clinical development for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in Phase 2 clinical development for the treatment of patients with heart failure.  Enrollment in the Company’s 388-patient Phase 3 study of vepoloxamer in patients with sickle cell disease, known as the EPIC study, was completed in February 2016.  Enrollment in the Company’s Phase 2 study of vepoloxamer in patients with chronic heart failure is ongoing.  AIR001, the Company’s second product candidate, is in Phase 2 clinical development for the treatment of patients with heart failure with preserved ejection fraction (HFpEF). Enrollment in a Phase 2a study of AIR001 in patients with HFpEF is ongoing and AIR001 was recently selected by the Heart Failure Clinical Research Network for evaluation in a 100-patient, multicenter, randomized, double-blind, placebo-controlled, Phase 2 study in patients with HFpEF.  More information can be found on the Company’s web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the Company’s current expectations and assumptions. Such forward-looking statements may be identified by the use of forward-looking words such as “intend,” “plan,” “anticipate,” “believe,” “expect,” among others, and include, but are not limited to, statements relating to prospects for successful development and commercialization of the Company’s product candidates, including vepoloxamer for the treatment of vaso-occlusive crisis of sickle cell disease, and anticipated timing of achievement of development milestones, such as commencement and completion of clinical studies and announcement of study data.  There are a number of factors that could cause or contribute to material differences between actual events or results and the expectations indicated by the forward-looking statements. These factors include, but are not limited to:  the inherent uncertainty of outcomes in ongoing and future studies of the Company’s product candidates and the risk that its product candidates may not demonstrate adequate safety, efficacy or tolerability in one or more such studies, including vepoloxamer in EPIC; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a “clinical hold,” and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; delays in clinical study closeouts, including blinded data review and quality control and assurance procedures; the risk that, even if current and planned clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the potential that, even if clinical studies of a product candidate in one indication are successful, clinical studies in another indication may not be successful; the Company’s dependence on third parties to assist with important aspects of development of its product candidates, including conduct of its clinical studies and supply and manufacture of clinical trial material, and, if approved, commercial product, and the risk that such third parties may fail to perform as expected, leading to delays in product candidate development or approval or inability to meet market demand for approved products, if any; the risk that the Company may be required to repay its outstanding debt obligations on an accelerated basis and/or at a time that could be detrimental to its financial condition, operations and/or business strategy, including the prepayment of $10 million of the principal balance if results from the EPIC study are not positive; risks associated with the Company’s ability to manage operating expenses and/or obtain additional funding to support its operations on a timely basis or on acceptable terms, or at all; the potential for the Company to significantly delay, reduce or discontinue current and/or planned development and commercial-readiness activities or sell or license its assets at inopportune times if it is unable to raise sufficient additional capital as needed; the risk that, even if the Company successfully develops a product candidate in one or more indications, it may not realize commercial success and may never achieve profitability; the risk that the Company is not able to obtain and maintain effective patent coverage or other market exclusivity protections for its products, if approved, without infringing the proprietary rights of others; and other risks and uncertainties more fully described in the Company’s press releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law. 

[Tables to Follow]  

Mast Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

 

Three months ended

December 31,

(Unaudited)

 

Year ended

December 31, (1)

2015

2014

2015

2014

Total net revenue

$

$

$

$

Operating expenses:

   Research and development

7,518

4,933

28,264

19,435

   Selling, general and administrative

2,515

2,396

10,963

9,488

   Transaction-related expenses

271

   Depreciation and amortization

41

25

146

85

      Total operating expenses

9,714

7,354

39,373

29,279

Loss from operations

(9,714)

(7,354)

(39,373)

(29,279)

Interest income, interest expense and other
income/(expense), net

(449)

41

(469)

577

Net loss

$

(10,163)

$

(7,313)

$

(39,842)

$

(28,702)

Net loss per share – basic and diluted

$

(0.06)

$

(0.05)

$

(0.25)

$

(0.23)

Weighted average shares – basic and diluted

163,614

145,257

162,219

122,409

 

(1)

The condensed consolidated statements of operations for the years ended December 31, 2015 and 2014 have been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for the complete financial statements.

 

Mast Therapeutics, Inc

Balance Sheet Data

(In thousands)

December 31,

2015

December 31,

2014

Cash, cash equivalents and investment securities

$              40,981

$            57,289

Working capital

19,079

49,965

Total assets

54,217

70,500

Total liabilities

30,328

11,842

Stockholders’ equity

23,889

58,658

 

Logo – http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a

 

SOURCE Mast Therapeutics, Inc.

Sorrento to Present at the 28th Annual ROTH Conference

March 14, 2016 – 4:00 am

SAN DIEGO, March 14, 2016 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Henry Ji, Ph.D., Chairman and CEO, will present at the 28th Annual ROTH Conference on Tuesday, March 15, 2016 from 7:00 am to 7:30 am PDT in Salon 6 – Yellow. The conference will take place at The Ritz-Carlton, Laguna Niguel in Dana Point, CA.

About Sorrento Therapeutics, Inc. 

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento’s lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

Sorrento™, and the Sorrento logo are trademarks owned by Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

© 2016 Sorrento Therapeutics

Logo – http://photos.prnewswire.com/prnh/20150105/167173LOGO

SOURCE Sorrento Therapeutics, Inc.

West Coast Bio Roundup: Illumina, CRISPR, Orexigen, Ambry & More

March 11, 2016 – 12:43 pm

El Niño-driven storms returned to California this week to fill up reservoirs and snarl commutes, although we’ve got nothing to compare with what’s happening down South. A few biotech…

[[Click headline to continue reading.]]

American Medical Association Grants New CPT Code for Microdeletion Testing

March 11, 2016 – 6:55 am

SAN CARLOS, Calif., March 11, 2016 /PRNewswire/ — Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced the American Medical Association (AMA) has approved Natera’s application for a Current Procedural Terminology, or CPT, code for fetal chromosomal microdeletion detection in circulating cell-free fetal DNA in maternal blood.  This code will be effective January 1, 2017.


Natera submitted an application for this code in 2015.  Before granting this code the AMA performed a review of the published literature on microdeletions, the technology available to screen for these disorders, and the current volume of testing.

“We are very pleased that the AMA has decided to grant a new CPT code for fetal chromosomal microdeletion detection in circulating cell-free fetal DNA in maternal blood,” said Matt Rabinowitz, CEO of Natera. “We believe the AMA’s action represents a critical step for strong reimbursement of microdeletions testing.”

About Natera

Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama® non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.

Forward-looking statements

This release contains forward-looking statements. All statements other than statements of historical facts contained in this press release, are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release. Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update the forward-looking statements for any reason after the date of this press release. These forward-looking statements are subject to a number of known and unknown risks and uncertainties that may cause actual results to differ materially, including uncertainty in the development and commercialization of Natera’s planned future cancer products or other new products or if the results of its clinical studies do not support the use of its tests, or cannot be replicated in later studies required for regulatory approvals or clearances. Additional risks and uncertainties are discussed in greater detail in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Natera’s Form 10-Q for the quarter ended September 30, 2015. Further information on potential risks that could affect actual results will be included in other filings Natera makes with the SEC from time to time. These documents are available for free on the company’s website at www.natera.com under the Investor Relations section, and on the SEC’s website at www.sec.gov.  

Contact
Natera, Inc.
Mike Brophy, Investor Relations, 650-249-9091 x 1471
mbrophy@natera.com

Logo – http://photos.prnewswire.com/prnh/20151112/286881LOGO

 

SOURCE Natera, Inc.

Imprimis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

March 11, 2016 – 6:45 am

SAN DIEGO, March 11, 2016 /PRNewswire/ — Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), (“Imprimis” or the “company”), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, announced today the pricing of an underwritten public offering of 2.9 million shares of its common stock at a price to the public of $3.60 per share, before underwriting discounts.  In addition, the company has granted the underwriters the option, exercisable for 45 days, to purchase an additional 435,000 shares of its common stock to cover over-allotments.  The offering is expected to close on or about March 16, 2016, subject to satisfaction of customary closing conditions. 

Imprimis anticipates using its net proceeds from the offering primarily for working capital and general corporate purposes, which may include, among other things, expenditures associated with the company’s efforts to transition its Texas and New Jersey facilities to current good manufacturing practices (cGMP) and register them with the U.S. Food and Drug Administration (FDA) as outsourcing facilities.

National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NASDAQ: NHLD), is acting as the sole book-running manager for the offering.   

A registration statement on Form S-3 relating to these securities was filed with the U.S. Securities and Exchange Commission (“SEC”) and was declared effective on September 29, 2014. The securities are being offered by means of a written prospectus supplement forming part of the effective registration statement. Copies of the prospectus and the final prospectus supplement relating to the offering have been filed with the SEC and may be obtained by request to the offices of National Securities Corporation, Attn: Kim Addarich, Senior Vice President, 410 Park Avenue, 14th Floor, New York, NY 10022, Email: Kaddarich@nhldcorp.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

ABOUT IMPRIMIS PHARMACEUTICALS

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The company’s two business programs, Imprimis Cares™ and Custom Compounding Choice™, focus on patient outcomes and affordability by offering high quality customizable compounded drugs in all 50 states. Headquartered in San Diego, California, Imprimis owns and operates four dispensing facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisPharma.com.  

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered forward looking statements, including statements regarding, among other things, the completion, timing, size and terms of the proposed public offering; the company’s planned use of any proceeds from the offering; and the company’s plans to upgrade and construct new pharmacy facilities and register these facilities as outsourcing facilities. Forward looking statements are based on management’s current views, expectations and assumptions and therefore are not guaranties of future performance and are subject to risks and uncertainties that may cause actual results to differ materially and adversely from those predicted by the forward looking statements.  Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, market and other general economic conditions; the company’s ability to satisfy the conditions required to complete the offering; and the company’s perception of future availability of equity or debt financing needed to fund the growth of its business. As a result of these risks and uncertainties, undue reliance should not be placed on forward looking statements. The limited information contained in this press release is not adequate for making an informed investment judgment about the company, and you are encouraged to read Imprimis’ filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q, which more fully describe the company and its business and the risks and uncertainties that may impact future performance. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. Forward looking statements speak only as of the date they are made and except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Contact
Bonnie Ortega
bortega@imprimispharma.com
858.704.4587

Logo – http://photos.prnewswire.com/prnh/20150108/167712LOGO

 

SOURCE Imprimis Pharmaceuticals, Inc.; National Holdings, Inc.

Trovagene Announces Fourth Quarter and Year End 2015 Financial Results

March 10, 2016 – 9:40 pm

SAN DIEGO, March 10, 2016 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and year ended December 31, 2015.

“2015 was our coming out year, as the introduction of our liquid biopsy solution for cancer monitoring was met with great response by physicians,” said Antonius Schuh, Ph.D., chief executive officer of Trovagene. “In support of our commercial efforts, we are assembling a compendium of clinical data, published manuscripts, and case studies in real-world settings that demonstrate the ability of our platform to improve the management of cancer patients by determining and tracking actionable oncogene mutations. Our goals for 2016 include increasing the number of oncologists using our assays in clinical practice, solidifying favorable health insurance reimbursement, and presenting and publishing additional clinical results from larger  data sets supporting the utility of our assay platform. Liquid biopsy for cancer monitoring offers tremendous potential, and we continue to be positioned well financially to execute on our business plan, improve the care of cancer patients, and increase stockholder value.”

Fourth Quarter Financial Results

For the fourth quarter ended December 31, 2015, Trovagene reported a net loss of $7.4 million, or $0.26 per fully diluted common share, as compared to a net loss of $4.7 million, or $0.25 per fully diluted common share, for the fourth quarter ended December 31, 2014. The change in net loss is primarily due to increased operating expenses.

Year End 2015 Financial Results

For the year ended December 31, 2015, Trovagene reported a net loss of $27.5 million, or $1.21 per fully diluted common share, as compared to a net loss of $14.3 million, or $0.88 per fully diluted common share, for the year ended December 31, 2014. The increase in net loss is primarily due to increased operating expenses versus the prior year comparable period.

Cash and Cash Equivalents

Trovagene had cash and cash equivalents of approximately $67.5 million on December 31, 2015, as compared to approximately $27.3 million on December 31, 2014.

Summary of 2015 Activities

Trovagene continues to advance its Precision Cancer Monitoring® (PCM) platform for the non-invasive monitoring of clinically actionable mutations for cancer patients. The Company currently has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic, and skin cancer. Trovagene remains focused on commercializing its highly sensitive and quantitative liquid biopsy service for cancer monitoring.

In 2015, the Company’s key accomplishments included the following:

Assembled commercial infrastructure and launched pilot marketing and sales program for Precision Cancer Monitoring platform

  • Four sales professionals initially in the field, generated strong interest and ordering of PCM tests by practicing oncologists
  • Trovagene Clinical Experience Program (CEP) deployed to enable trial use of technology by oncologists

Presented clinical study results at several medical and scientific conferences

  • 2015 European Cancer Congress (ECC)
    • Quantitative detection and monitoring of circulating tumor DNA (ctDNA) and driver mutations can be used to rapidly determine treatment response
  • World Lung Congress on Lung Cancer
    • Urine-based liquid biopsy platform shown to detect the impact of cancer therapy within 24 hours
  • Next Generation DX summit
    • Clinical data in lung, colorectal, and pancreatic cancer demonstrate the utility of Trovagene’s PCM platform as an important disease management tool
  • 2015 American Association for Cancer Research Annual Meeting
    • Studies highlighted clinical utilities and advantages of Trovagene’s PCM platform, including the ability to obtain significantly more ctDNA from urine samples versus plasma samples
  • Association for Value-Based Cancer Care Meeting
    • Cost-benefit analysis of Trovagene’s PCM platform demonstrated that the use of urinary liquid biopsy can significantly reduce costs when compared to tissue biopsy
  • 2015 American Society of Clinical Oncology Annual Meeting
    • Studies addressed advantages of liquid biopsy over tissue biopsy and demonstrated ability to monitor tumor dynamics in lung, pancreatic, and colon cancers

Initiated study to monitor response to immunotherapy in melanoma patients  

  • Study objective is to deliver a urinary liquid biopsy-based solution to provide faster and more accurate information for measuring response to immunotherapy

Strengthened balance sheet through two offerings of common stock

  • Raised aggregate gross proceeds of approximately $63 million

Formed Trovagene Srl, also known as the Trovagene Research Institute, a European subsidiary

2016 Goals and Objectives

  • Continue to build clinical evidence supporting the use of Trovagene’s PCM platform
    • Submit 8 or more abstracts for presentation at key medical meetings in 2016
    • Submit up to 9 clinical and scientific manuscripts for publication that demonstrate the technical advantages and clinical utility of Trovagene’s PCM platform
  • Establish advantageous reimbursement relationships with third party administrators
    • Secure agreements representing more than 100 million covered lives
    • Finalize  comprehensive health-economic study plan
  • Establish marketing and adoption parameters
    • Ensure high clinical interest and strong service levels
    • Expand sales and marketing presence in the oncology market
    • Conduct and document real-world case studies
  • Engage in strategic partnerships for clinical trial service agreements and translational research collaborations, and to expand global presence
  • Conduct  clinical studies with top academic institutions and comprehensive cancer centers

Trovagene will hold a conference call today at 5:00 p.m. Eastern Standard Time (2:00 p.m. Pacific Standard Time) to review its fourth quarter and year end 2015 financial results. A live webcast of the Company’s conference call will be available online at http://trovagene.investorroom.com/events. To access the conference call, please dial (888) 347-6081 (domestic), (412) 902-4285 (international), or (855) 669-9657 (Canada), conference ID# 10078930. To access a telephone replay of the call, dial (877) 344-7529 (domestic), (412) 317-0088 (international), or (855) 669-9658 (Canada), replay ID# 10078930. The replay will be available one hour after the conclusion of the call. The webcast and telephone replay will be archived on the Company’s website following the conference. 

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Trovagene’s expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition;  our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technologies or products will be utilized by oncologists or prove to be commercially successful, that Trovagene’s PCM platform will ultimately be successful or result in better reimbursement outcomes or that Trovagene will meet any of its 2016 goals and objectives. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene’s most recent Annual Report on Form 10-K and its other periodic reports filed with the Securities and Exchange Commission.

(Financial Information to Follow)

Contact

Investor Relations

Media Relations

David Moskowitz and Amy Caterina

Investor Relations

Jody LoMenzo

Corporate Practice Counsel

Trovagene, Inc.

Inventiv Health Public Relations

858-952-7593

212-364-0458

ir@trovagene.com

Jody.LoMenzo@inventivhealth.com

 

Trovagene, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except for per share amounts)

Three Months Ended

December 31,

Year Ended

December 31,

2015

2014

2015

2014

Revenue:

Royalty income

$

52

$

56

$

275

$

270

License fees

10

Diagnostic service revenue

3

14

Other revenue

24

24

Total Revenue

79

56

313

280

Costs and expenses:

Cost of revenue

199

15

629

15

Research and development

3,166

1,835

10,594

6,665

Selling and marketing

1,935

1,035

6,444

2,735

General and administrative

2,164

1,675

7,920

5,810

Total operating expenses

7,464

4,560

25,587

15,225

Loss from operations

(7,385)

(4,504)

(25,274)

(14,945)

Other income (expense):

   Net interest expense

(368)

(384)

(1,468)

(831)

   Gain (loss) on change in fair value of derivative instruments- warrants

379

205

(726)

1,426

   Other (income) loss, net

(7)

(3)

25

Net loss and comprehensive loss

$

(7,381)

$

(4,683)

$

(27,471)

$

(14,325)

Preferred stock dividend

(6)

(6)

(24)

(23)

Net loss and comprehensive loss attributable to common stockholders

$

(7,387)

$

(4,689)

$

(27,495)

$

(14,348)

Net loss per common share – basic

$

(0.25)

$

(0.25)

$

(1.05)

$

(0.76)

Net loss per common share – diluted

$

(0.26)

$

(0.25)

$

(1.21)

$

(0.88)

Weighted average shares outstanding – basic

29,723

18,904

26,202

18,904

Weighted average shares outstanding – diluted

30,157

19,071

26,452

19,071

 

Trovagene, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

December 31,

2015

December 31,

2014

Assets

Current assets:

Cash and cash equivalents

$

67,493

$

27,294

Accounts receivable

99

57

Prepaid expense and other assets

789

369

Total current assets

68,381

27,720

Property and equipment, net

2,691

840

Other assets

374

337

Total Assets

$

71,446

$

28,897

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

1,041

$

748

Accrued expenses

1,935

1,842

Current portion of long-term debt

5,226

1,898

Total current liabilities

8,202

4,488

Long-term debt, less current portion

11,246

13,053

Derivative financial instruments

3,297

3,006

Total Liabilities

22,745

20,547

Stockholders’ equity

48,701

8,350

Total liabilities and stockholders’ equity

$

71,446

$

28,897

 

Logo – http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

 

SOURCE Trovagene, Inc.

Pfenex Reports Fourth Quarter and Full Year 2015 Results and Provides Business Update

March 10, 2016 – 2:05 pm

SAN DIEGO, March 10, 2016 /PRNewswire/ — Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a business update.

“2015 was a very productive and eventful year for Pfenex,” stated Bertrand C. Liang, chief executive officer of Pfenex.  “We signed the collaboration agreement for PF582, our biosimilar candidate to Lucentis, with Hospira, now a subsidiary of Pfizer (together, Pfizer) in February 2015, we led our successful secondary offering in April 2015 and we signed a significant contract with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS) for the advanced development of our anthrax vaccine in August 2015.  2015 was also a year marked by the continued successful progress of our portfolio of biosimilar and vaccine candidates and by the strengthening of Pfenex through key additions to our company and to our board of directors.  2016 should be an exciting year for Pfenex as we look to continue our successful pipeline advancement and provide updates on our key milestones throughout the year.”

Business Updates and 2015 Highlights

  • Pfenex initiated a Phase 1 trial of PF530, a biosimilar candidate to Betaseron, in the first quarter of 2015 and enrolled 12 healthy subjects.  Based on the analysis of the trial PK and PD parameters, no statistical differences between PF530 compared to the reference compound were observed.  The pivotal PK/PD study and immunogenicity trial are expected to initiate in 2H2016.
  • PF708, our peptide candidate that we are developing as a therapeutic equivalent to Forteo, initiated a bioequivalence study in 2015 and we expect to provide a data read-out from that study in 2H2016.   
  • The pivotal clinical comparator trial for PF582, our biosimilar candidate to Lucentis, is expected to initiate in 2016. We entered into a collaboration with Pfizer in February 2015.  The collaboration included an upfront payment of $51 million and milestone payments valued at up to $291 million as well as tiered double digit royalties on net sales of PF582. Pfizer is responsible for the clinical comparative trial and we will share costs of the trial 50/50 up to a cap for Pfenex of $20 million, with $10 million of that amount offset as a credit against the royalties payable to us.
  • Pfenex initiated the Phase 1 trial for its recombinant anthrax vaccine in 2015 and expects an interim data read-out in 2H2016.  In August, Pfenex announced it had signed a five year, cost plus fixed fee contract valued at up to $143.5 million with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the advanced development of our mutant recombinant protective antigen anthrax vaccine which offers the potential for a dramatic improvement in the rapid production of large amounts of high value stable recombinant anthrax vaccine for the U.S. Government.
  • During 2015 we further strengthened our board of directors.  In September 2015, we announced that Dennis M. Fenton, Ph.D., was appointed to the company’s board of directors, deepening the manufacturing and product development expertise of the biosimilar company. Dr. Fenton has over three decades of experience in the biotechnology industry. Additionally, in April 2015 we announced that John Taylor was elected to the company’s board of directors.  Mr. Taylor brings more than 20 years of regulatory experience working with the U.S. Food and Drug Administration (FDA).
  • In April 2015, Pfenex announced the closing of our follow on offering. The net proceeds to Pfenex from this offering were approximately $38.0 million, after deducting underwriting discounts and commissions but before deducting estimated offering expenses.

Financial Highlights for the Fourth Quarter

Total Revenue increased by $1.2 million, or 62%, to $3.3 million for the quarter ended December 31, 2015 compared to $2.0 million in same period in 2014. The increase in revenue was due to the stage of development of our Px563L product candidate under our government contracts and by an increase in license revenue from our collaboration with Pfizer, partially offset by a decline in protein production services. We expect revenue related to our protein production services to decline in the near-term as we shift our resources to developing our product pipeline.

Cost of revenue increased by approximately $0.5 million, or 44%, to $1.7 million in the three month period ended December 31, 2015 compared to $1.2 million in same period in 2014. The increase in cost of revenue was due primarily to the stage of development of our Px563L product candidate under our government contracts. Given the nature of the novel vaccine development process, these costs will fluctuate depending on stage of development.

Research and development expenses increased by approximately $4.7 million, or 355%, to $6.1 million in the three month period ended December 31, 2015 compared to $1.3 million in same period in 2014. The increase in research and development expenses was due primarily to the increase in development activity on our product candidates PF708, PF530 and PF529 and the hiring of additional personnel dedicated to our research and development efforts. We expect research and development costs will increase going forward as we independently advance PF530 as a wholly-owned product candidate, as well as continuing to advance our wholly-owned pipeline including PF708, our therapeutic equivalent candidate to Forteo, and PF529, our biosimilar candidate to Neulasta. Additionally, we expect research and development expenses to increase as we advance our other lead candidates and pipeline product candidates. For example, under our agreement with Pfizer, we will share the confirmatory clinical study costs for PF582 with our share capped at $20 million, $10 million of which will be setoff as a credit against royalties payable to us unless the collaboration agreement is terminated prior to such setoff.

Selling, general and administrative expenses increased by $0.7 million, or 23%, to $3.7 million in the three month period ended December 31, 2015 compared to $3.0 million in the same period in 2014. The increase in selling, general and administrative expenses was due to an increase in activities associated with operating as a publicly-traded company. We expect general and administrative costs to increase for activities associated with company operations. These increases will likely include the hiring of additional personnel. In addition, we intend to continue to incur increased internal and external business development costs to support our various product development efforts, which can vary from period to period.

Cash and cash equivalents as of December 31, 2015 was $106.2 million.

Cautionary Note Regarding Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Pfenex’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Pfenex’s expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding the future potential of Pfenex’s product candidates, including future plans to develop, manufacture and commercialize its product candidates and the potential to receive future milestone and royalty payments under its collaboration agreements; Pfenex’s expectations regarding the timing of the release of additional data and results for its product candidates, and the timing of the initiation of additional studies for its product candidates; and Pfenex’s future projections related to increases in expenses and reductions in protein production revenue. Pfenex’s expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Actual results may differ materially from those indicated by these forward-looking statements as a result of the uncertainties inherent in the clinical drug development process, including, without limitation, Pfenex’s ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates or may require Pfenex to conduct additional clinical trials or modify ongoing clinical trials; challenges related to commencement, patient enrollment, completion, and analysis of clinical trials; difficulties in achieving and demonstrating biosimilarity in formulations; Pfenex’s ability to manage operating expenses; Pfenex’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives; Pfenex’s dependence on third parties for development, manufacture, marketing, sales and distribution of products; unexpected expenditures; and difficulties in obtaining and maintaining intellectual property protection for its product candidates. Information on these and additional risks, uncertainties, and other information affecting Pfenex’s business and operating results is contained in Pfenex’s Annual Report on Form 10-K for the year ended December 31, 2014 and in Pfenex’s subsequent reports on Form 10-Q and Form 8-K, filed with the Securities and Exchange Commission. Additional information will also be set forth in Pfenex’s Annual Report on Form 10-K for the period ended December 31, 2015 to be filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Pfenex as of the date hereof, and Pfenex disclaims any obligation to update any forward-looking statements, except as required by law.

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (http://www.pfenex.com/), our investor relations website (http://pfenex.investorroom.com/), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time. For a link to our most recent corporate presentation, visit our investor relations website (http://pfenex.investorroom.com/).

About Pfenex Inc.

Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company’s lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines,therapeutic equivalents to reference listed drug products, and next generation biologics.

 

PFENEX INC.

Condensed Consolidated Statements of Operations

Three Months Ended
December 31,

(unaudited)

Twelve months ended
December 31,

(audited)

(in thousands, except per share data)

2015

2014

2015

2014

Revenue

$      3,261

$      2,019

$       9,583

$    10,644

Cost of revenue

1,729

1,202

4,640

7,233

Gross profit

1,532

817

4,943

3,411

Operating expense

Selling, general and administrative

3,743

3,037

14,598

9,003

Research and development

6,085

1,336

18,183

4,125

Total operating expense

9,828

4,373

32,781

13,128

Loss from operations

(8,296)

(3,556)

(27,838)

(9,717)

Other income (expense), net

36

(19)

74

(77)

Net loss before income taxes

(8,260)

(3,575)

(27,764)

(9,794)

Income tax benefit (expense)

(411)

1

(452)

Net loss

$     (8,671)

$     (3,574)

$    (28,216)

$     (9,794)

Net loss per common share basic and diluted

$       (0.37)

$       (0.18)

$        (1.26)

$       (1.04 )

Weighted-average common shares used to compute basic and diluted net loss per share

23,295

20,388

22,376

9,441

 

PFENEX INC.

Consolidated Balance Sheets

December 31,

2015

2014

(in thousands)

Assets

Current assets

Cash and cash equivalents

$     106,162

$       45,722

Restricted cash

3,959

Accounts and unbilled receivables, net

2,683

1,584

Inventories

24

23

Income tax receivable

508

402

Deferred income taxes

3,281

Other current assets

1,694

1,753

Total current assets

115,030

52,765

Restricted cash

3,955

Deferred income taxes

1,955

Property and equipment, net

3,179

2,310

Other long term assets

121

53

Intangible assets, net

5,832

6,363

Goodwill

5,577

5,577

Total assets

$     131,694

$       71,023

Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity

Current liabilities

Accounts payable

$             886

$          1,129

Accrued liabilities

5,997

2,633

Current portion of deferred revenue

3,870

201

Line of credit obligation

3,813

3,813

Income tax payable

1,676

Total current liabilities

16,242

7,776

Deferred revenue, less current portion

44,225

Deferred tax liability

3,281

Other long-term liabilities

46

92

Total liabilities

60,513

11,149

Commitments and contingencies

Stockholders’ equity

Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding

Common stock, par value $0.001, 200,000,000 shares authorized at December 31, 2015 and 2014, respectively, 23,316,413 and 20,405,066 shares issued and outstanding at December 31, 2015 and 2014, respectively

24

21

Additional paid-in capital

212,661

173,141

Accumulated deficit

(141,504)

(113,288)

Total stockholders’ equity

71,181

59,874

Total liabilities and stockholders’ equity

$     131,694

$       71,023

 

 

SOURCE Pfenex Inc.

Imprimis Pharmaceuticals Announces Proposed Public Offering of Common Stock

March 10, 2016 – 2:05 pm

SAN DIEGO, March 10, 2016 /PRNewswire/ — Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), (“Imprimis” or the “company”), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, announced today a proposed underwritten public offering of its common stock, subject to market and other conditions. In connection with the offering, the company intends to grant the underwriters the option, exercisable for 45 days, to purchase additional shares equal to up to 15% of the aggregate number of shares sold in the offering to cover over-allotments. 

National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NASDAQ:NHLD), is acting as the sole book-running manager for the offering.   

A registration statement on Form S-3 relating to these securities was filed with the U.S. Securities and Exchange Commission (“SEC”) and was declared effective on September 29, 2014. The securities may be offered only by means of a prospectus. Copies of the prospectus and a preliminary prospectus supplement relating to the offering have been filed with the SEC and may be obtained by request to the offices of National Securities Corporation, Attn: Kim Addarich, Senior Vice President, 410 Park Avenue, 14th Floor, New York, NY 10022, Email: Kaddarich@nhldcorp.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

ABOUT IMPRIMIS PHARMACEUTICALS

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The company’s two business programs, Imprimis Cares™ and Custom Compounding Choice™, focus on patient outcomes and affordability by offering high quality customizable compounded drugs in all 50 states.  Headquartered in San Diego, California, Imprimis owns and operates four dispensing facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisPharma.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered forward looking statements, including statements regarding, among other things, the completion, timing, size and terms of the proposed public offering. Forward looking statements are based on management’s current views, expectations and assumptions and therefore are not guaranties of future performance and are subject to risks and uncertainties that may cause actual results to differ materially and adversely from those predicted by the forward looking statements.  Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, market and other general economic conditions; the company’s ability to satisfy the conditions required to complete the offering; and the company’s perception of future availability of equity or debt financing needed to fund the growth of its business. As a result of these risks and uncertainties, undue reliance should not be placed on forward looking statements. The limited information contained in this press release is not adequate for making an informed investment judgment about the company, and you are encouraged to read Imprimis’ filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q, which more fully describe the company and its business and the risks and uncertainties that may impact future performance. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. Forward looking statements speak only as of the date they are made and except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Contact
Bonnie Ortega
bortega@imprimispharma.com
858.704.4587

Logo – http://photos.prnewswire.com/prnh/20150108/167712LOGO

 

SOURCE Imprimis Pharmaceuticals, Inc.; National Holdings, Inc.

Symic to Present at the 13th Annual BIO Asia International Conference

March 10, 2016 – 8:00 am

SAN FRANCISCO, March 10, 2016 /PRNewswire/ — Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, will present…